1-3 of 3
Karl Runge
Close
Sort by
Journal Articles

Preclinical Validation Studies Support Causal Machine Learning Based Identification of Novel Drug Targets for High-Risk Multiple Myeloma

Arnold Bolomsky, Fred Gruber, PhD, Kathrin Stangelberger, MSc, Leon Furchtgott, PhD, Dominik Arnold, Puja Raut, Diane Wuest, PhD, Karl Runge, Iya Khalil, Niklas Zojer, MD, Nikhil Munshi, MD, Boris Hayete, PhD, Heinz Ludwig, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3210.
https://doi.org/10.1182/blood-2018-99-117886
Published: 2018
Journal Articles

Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified By Causal Machine Learning: Out-of-Cohort and Experimental Validation

Leon Furchtgott, PhD, Arnold Bolomsky, PhD, Fred Gruber, PhD, Mehmet Kemal Samur, PhD, Jonathan J. Keats, PhD, Jennifer Yesil, MS, Kathrin Stangelberger, MSc, Michel Attal, MD PhD, Philippe Moreau, MDPhD, Hervé Avet-Loiseau, MD PhD, Karl Runge, PhD, Diane Wuest, PhD, Kelly Rich, Iya Khalil, PhD, Boris Hayete, PhD, Heinz Ludwig, MD, Nikhil Munshi, MD, Daniel Auclair, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3029.
https://doi.org/10.1182/blood.V130.Suppl_1.3029.3029
Published: 2017
Journal Articles

Bayesian Network Models of Multiple Myeloma: Drivers of High Risk and Durable Response

Fred Gruber, PhD, Jonathan J Keats, PhD, Kyle McBride, MS, Karl Runge, PhD, Diane Wuest, Tiffany Hadzi, Mary Derome, MS, Sagar Lonial, MD FACP, Iya Khalil, PhD, Boris Hayete, Daniel Auclair, PhD
Journal: Blood
Blood (2016) 128 (22): 4406.
https://doi.org/10.1182/blood.V128.22.4406.4406
Published: 2016